It’s been a crucial week for Prothena Corporation plc (NASDAQ:PRTA); here’s what analysts have to say.

November 10, 2018 - By Peter Kolinski

Prothena Corporation plc (NASDAQ:PRTA) LogoInvestors sentiment decreased to 0.86 in Q2 2018. Its down 0.03, from 0.89 in 2018Q1. It worsened, as 31 investors sold Prothena Corporation plc shares while 28 reduced holdings. 20 funds opened positions while 31 raised stakes. 29.12 million shares or 2.41% less from 29.85 million shares in 2018Q1 were reported.
Clearbridge Limited Liability Com holds 0% or 24 shares. National Bank Of America De holds 0% or 175,919 shares in its portfolio. Price Mgmt Inc holds 0.34% or 47,232 shares in its portfolio. Jpmorgan Chase accumulated 8,160 shares. Schwab Charles Invest Inc stated it has 204,787 shares. The Japan-based Daiwa Secs Group has invested 0% in Prothena Corporation plc (NASDAQ:PRTA). Wells Fargo Mn has 21,507 shares. Citigroup stated it has 114,050 shares or 0% of all its holdings. Geode Capital Limited Liability Company has 0% invested in Prothena Corporation plc (NASDAQ:PRTA). Dimensional Fund Advsr Limited Partnership reported 535,060 shares or 0% of all its holdings. Ftb Advsrs Incorporated stated it has 6 shares or 0% of all its holdings. Oppenheimer reported 0% stake. Credit Suisse Ag holds 40,778 shares or 0% of its portfolio. The Minnesota-based Thrivent Financial For Lutherans has invested 0% in Prothena Corporation plc (NASDAQ:PRTA). Alliancebernstein Limited Partnership holds 0% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA) for 56,140 shares.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Coverage

Among 2 analysts covering Prothena Corp (NASDAQ:PRTA), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. Prothena Corp had 2 analyst reports since May 21, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained it with “Overweight” rating and $18 target in Friday, June 15 report. On Monday, May 21 the stock rating was downgraded by Barclays Capital to “Sell”. Below is a list of Prothena Corporation plc (NASDAQ:PRTA) latest ratings and price target changes.

15/06/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Overweight Old Target: $14 New Target: $18 Maintain
21/05/2018 Broker: Barclays Capital Rating: Sell New Target: $12.0000 Downgrade

The stock decreased 3.87% or $0.5 during the last trading session, reaching $12.41. About 507,069 shares traded or 11.54% up from the average. Prothena Corporation plc (NASDAQ:PRTA) has declined 77.78% since November 10, 2017 and is downtrending. It has underperformed by 93.40% the S&P500.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The company has market cap of $494.38 million. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. It currently has negative earnings. The firm has a license, development, and commercialization agreement with F.

More news for Prothena Corporation plc (NASDAQ:PRTA) were recently published by: Nasdaq.com, which released: “Prothena to Report Third Quarter 2018 Financial Results on November 6” on October 30, 2018. Nasdaq.com‘s article titled: “Prothena Reports Third Quarter 2018 Financial Results and Provides R&D Update” and published on November 06, 2018 is yet another important article.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>